Financial Reports & KPI Analysis

JiduffKelv Digital Accounting Mock Company Reports 

The screenshot presents selected financial reports from the JiduffKelv Digital Accounting Mock Company in QuickBooks Online. Each screenshot demonstrates how transactions and reconciliations feed into key reports such as Profit & Loss, Balance Sheet, Statements of Cash Flow, Aged Receivables and Aged Payables providing a clear, accurate view of the company’s financial health and performance.

Profit & Loss Statement — Financial Interpretation & KPI Analysis

Report Overview

Company: JiduffKelv Pharmaceutical Ltd
Report Type: Profit & Loss Statement
Period: January 1 – May 19, 2026
Accounting Method: Accrual Basis

Executive Financial Interpretation:  The Profit & Loss Statement reflects strong revenue generation and positive profitability performance during the reporting period. The business generated income primarily from pharmaceutical product sales, consultation services, and medication-related services, resulting in total revenue of approximately $50,362.02.

The company maintained a positive gross profit position despite high inventory-related costs, indicating that product sales are sufficiently covering direct operational costs. Net earnings of approximately $10,317.76 demonstrate that the business remained profitable after accounting for operating expenses, depreciation, utilities, salaries, and administrative costs.

The report also reflects the application of accrual accounting principles through the recognition of depreciation expenses, utilities, and prepaid expense adjustments, resulting in more accurate financial reporting and period matching.

Key Financial Highlights

Total Revenue

Approximately $50,362.02

Revenue Sources:

• OTC Sales contributed the largest portion of revenue

• Prescription Drug Sales generated significant recurring income

• Consultation and Medication Services provided additional service-based revenue diversification

Insight: The company demonstrates a diversified income structure, reducing overreliance on a single revenue stream.

Cost of Sales Analysis

Total Cost of Sales:

Approximately $34,398.00

Major Cost Drivers:

• Cost of Drugs Sold

• Medical Supplies Consumption

• Inventory-related adjustments

Insight: Inventory and pharmaceutical supply costs represent the largest operational cost category, which is expected within the pharmaceutical industry.

Gross Profit Analysis

Gross Profit:

Approximately $15,964.02

Gross Profit Margin:

Approximately 31.7%

KPI Interpretation: A gross margin of 31.7% indicates that the company retains approximately $0.32 from every dollar of revenue after covering direct inventory and product-related costs.

Strategic Observation: The gross margin suggests effective pricing and inventory management, although continued monitoring of inventory shrinkage and supply costs is important to preserve profitability.

Operating Expense Analysis

Total Operating Expenses:

Approximately $5,656.26

Major Expense Categories:

• Office Expenses

• Salaries & Wages

• Depreciation Expense

• Travel Expenses

• Utilities Expenses

Insight: Administrative and operational expenses remain relatively controlled compared to total revenue, supporting overall profitability.

Expense Ratio Analysis

Operating Expense Ratio:

Approximately 11.2% of revenue

KPI Interpretation: The business spends approximately $0.11 in operating expenses for every $1 generated in revenue.

Strategic Observation: This reflects relatively efficient operational cost management for a growing pharmaceutical operation.

Net Profit Analysis

Net Income:

Approximately $10,317.76

Net Profit Margin:

Approximately 20.5%

KPI Interpretation: The company retains approximately $0.21 in profit from every $1 of revenue after covering all expenses.

Strategic Observation: A net margin above 20% reflects strong profitability and indicates healthy operational performance during the reporting period

Operational Observations

Positive Indicators:

Strong product sales revenue
Positive net earnings
Diversified revenue streams
Controlled operating expenses
Proper accrual adjustments reflected

Areas Requiring Monitoring:

Inventory shrinkage
Cost of drug supplies
Increasing operational overhead as business scales
Expense concentration in office and salary-related costs

Accounting & Reporting Strength Demonstrated

This report demonstrates:

• Accurate transaction classification

• Proper accrual accounting application

• Expense matching principles

• Depreciation recognition

• Financial statement preparation

• Profitability analysis

• KPI interpretation and reporting

Financial Insight: The financial performance of JiduffKelv Pharmaceutical Ltd reflects a profitable and operationally active business with strong product-driven revenue generation, controlled operating expenses, and positive net earnings. The company maintains healthy profitability margins while demonstrating appropriate application of accrual accounting and financial reporting principles.

Balance Sheet — Financial Interpretation & KPI Analysis

Report Overview

Company: JiduffKelv Pharmaceutical Ltd
Report Type: Balance Sheet
Reporting Date: May 19, 2026
Accounting Method: Accrual Basis

Executive Financial Interpretation: The Balance Sheet reflects a financially stable business with a strong asset position, significant liquidity, and positive shareholder equity. The company maintains substantial current assets primarily driven by cash balances, accounts receivable, and pharmaceutical inventory holdings.

The report also demonstrates proper application of accrual accounting principles through the recognition of prepaid expenses, accumulated depreciation, accounts payable, and fixed asset classifications. Overall, the company appears adequately capitalized and operationally positioned to support ongoing business activities.

Asset Structure Analysis

Total Assets

Approximately $575,934.44

The company’s assets are primarily concentrated in:

• Cash & Bank Balances

• Inventory Assets

• Accounts Receivable

• Property, Plant & Equipment (PPE)

Liquidity & Cash Position

Total Bank Balances:

Approximately $250,241.57

Accounts:

• Bank of America Savings Account

• Chase Bank Current Account

KPI Interpretation: The company maintains a strong cash position, indicating healthy liquidity and sufficient short-term financial flexibility.

Strategic Observation: Strong cash reserves improve the company’s ability to fund operations, purchase inventory, and meet financial obligations without immediate financing pressure.

Inventory Analysis

Total Inventory Assets:

Approximately $218,250.50

Inventory Composition:

• Drug Inventory

• Medical Supplies Inventory

KPI Interpretation: Inventory represents one of the largest asset categories, which is typical for a pharmaceutical business dependent on product availability and stock management.

Strategic Observation: High inventory levels support sales continuity but also require effective inventory turnover management to reduce shrinkage, expiry risks, and carrying costs.

Accounts Receivable Analysis

Accounts Receivable:

Approximately $46,332.23

KPI Interpretation: The company has a moderate level of outstanding customer balances awaiting collection.

Strategic Observation: Effective receivable collection procedures will be important to maintain cash flow efficiency and reduce potential bad debt exposure.

Fixed Asset Analysis

Property, Plant & Equipment (PPE):

Approximately $36,199.99

Additional Long-Term Assets:

• Vehicles

• Furniture & Fixtures

• Medical Equipment

• Computer Equipment

• Office Equipment

Accumulated Depreciation: Recognized appropriately across multiple asset classes.

KPI Interpretation: The company has invested significantly in operational infrastructure and recognizes depreciation properly under accrual accounting principles.

Strategic Observation: Proper depreciation tracking strengthens financial accuracy and demonstrates compliance with accounting standards.

Liability Analysis

Current Liabilities:

Approximately ($1,033.32) reflected after offsets

Major Liability Categories:

• Accounts Payable

• Credit Card Balances

• VAT Control Accounts

Observation: Liability balances appear relatively low compared to current assets, indicating strong short-term solvency.

Important Note: Some balances appear affected by offsetting or adjustment entries, which may require further review for presentation consistency.

Shareholders’ Equity Analysis

Total Shareholders’ Equity:

Approximately $576,967.76

Components:

• Share Capital

• Retained Earnings

• Current Net Income

KPI Interpretation: The business is strongly equity-funded, reflecting positive retained profitability and shareholder investment support.

Strategic Observation: Strong equity positioning improves financial stability and reduces dependence on external borrowing.

Key Financial Ratios & KPIs

Current Ratio

Estimated significantly above 1:1

Interpretation: The company possesses more than enough current assets to settle short-term obligations.

Working Capital

Strong positive working capital position.

Interpretation: Current assets substantially exceed current liabilities, supporting operational continuity and liquidity stability.

Debt Position

Low liability exposure relative to total assets.

Interpretation: The company appears conservatively leveraged with minimal financial pressure from debt obligations.

Operational Observations

Positive Indicators:

Strong liquidity position
High shareholder equity
Proper fixed asset recognition
Accrual accounting compliance
Positive retained profitability
Significant operational asset base

Areas Requiring Monitoring:

Inventory concentration and turnover
Receivable collection efficiency
Negative/offset liability presentation review
Asset utilization efficiency

Accounting & Reporting Strength Demonstrated

This Balance Sheet demonstrates:

• Proper asset classification

• Prepaid expense recognition

• Fixed asset accounting

• Depreciation tracking

• Liability management

• Equity reporting

• Accrual accounting application

• Financial position analysis

Financial Insight:  The Balance Sheet of JiduffKelv Pharmaceutical Ltd reflects a financially stable and well-capitalized business with strong liquidity, substantial inventory investment, and positive shareholder equity. The company demonstrates appropriate application of accrual accounting principles, effective asset structuring, and healthy financial positioning capable of supporting ongoing operational growth.

Statement of Cash Flows — Financial Interpretation & KPI Analysis

Report Overview

Company: JiduffKelv Pharmaceutical Ltd
Report Type: Statement of Cash Flows
Period: January 1 – May 19, 2026
Accounting Method: Accrual Basis

Executive Financial Interpretation:  The Statement of Cash Flows reflects the movement of cash through the company’s operating, investing, and financing activities during the reporting period. The report demonstrates that the business generated strong financing inflows and invested significantly in operational assets and inventory to support future growth.

Although operating cash flow reflects a negative position during the period, this appears primarily driven by substantial increases in inventory holdings and accounts receivable, indicating expansion of operational activities rather than immediate financial distress.

The company also invested heavily in long-term assets such as medical equipment, office equipment, furniture, and vehicles, demonstrating active infrastructure development and operational scaling.

Cash Flow from Operating Activities

Net Cash from Operating Activities:

Approximately ($255,870.71)

Key Drivers:

• Increase in inventory balances

• Growth in accounts receivable

• Working capital expansion

• Prepaid expense allocations

KPI Interpretation: Negative operating cash flow during a growth phase may indicate that the business is investing heavily in inventory and extending credit to customers to support revenue expansion.

Strategic Observation: While profitability remains positive, effective working capital management will be essential to maintain sustainable operational liquidity.

Working Capital Analysis

Inventory Growth:

Significant increase in pharmaceutical and medical supply inventory.

Insight: The business appears to be positioning itself for increased sales capacity and operational expansion.

Accounts Receivable Impact:

Customer balances increased during the reporting period.

Insight: Revenue generation is occurring, but a portion of cash remains tied up in outstanding customer collections.

Cash Flow from Investing Activities

Net Cash Used in Investing Activities:

Approximately ($60,537.72)

Major Investments:

• Medical Equipment

• Computer Equipment

• Office Equipment

• Vehicles

• Furniture & Fixtures

KPI Interpretation: The company is actively investing in long-term operational infrastructure and business capacity.

Strategic Observation: These investments support future operational efficiency and revenue generation potential.

Cash Flow from Financing Activities

Net Cash from Financing Activities:

Approximately $566,650.00

Major Financing Sources:

• Shareholder capital contributions

• Equity financing injections

KPI Interpretation: The company’s operations and expansion activities are currently being strongly supported through shareholder funding.

Strategic Observation: Strong equity financing reduces immediate debt pressure and supports business growth initiatives.

Net Cash Position

Net Increase in Cash:

Approximately $250,241.57

Ending Cash Balance:

Approximately $250,241.57

KPI Interpretation: Despite negative operating cash flow, the company maintained a strong overall cash position due to financing inflows.

Strategic Observation: The business currently has sufficient liquidity to sustain operations and support expansion activities.

Operational Observations

Positive Indicators:

Strong financing support
Significant infrastructure investment
Positive ending cash position
Active business expansion
Proper cash flow classification

Areas Requiring Monitoring:

Operating cash flow efficiency
Accounts receivable collections
Inventory turnover management
Long-term sustainability of financing dependency

Accounting & Reporting Strength Demonstrated

This report demonstrates:

• Cash flow preparation

• Operating vs investing vs financing classification

• Working capital analysis

• Fixed asset investment tracking

• Liquidity evaluation

• Financial reporting interpretation

• Accrual-to-cash flow relationship analysis

Financial Insight:  The Statement of Cash Flows reflects a growth-oriented business actively investing in inventory, infrastructure, and operational capacity while being strongly supported through shareholder financing. Although operating cash flow is currently negative due to working capital expansion, the company maintains a healthy overall liquidity position capable of supporting continued business growth and operational development.

Accounts Receivable (A/R) Ageing Summary Report — Financial Interpretation & KPI Analysis

Report Overview

Company: JiduffKelv Pharmaceutical Ltd
Report Type: Accounts Receivable (A/R) Ageing Summary Report
Periods Reviewed:

• May 31, 2026

• June 30, 2026

• July 31, 2026

Accounting Method: Accrual Basis

Executive Financial Interpretation: The Accounts Receivable Ageing Summary Report provides a breakdown of outstanding customer balances based on the length of time invoices have remained unpaid. This report demonstrates effective receivable monitoring, customer balance tracking, and credit control analysis within QuickBooks Online.

The ageing movement across the three reporting periods shows how unpaid balances gradually transitioned from current receivables into older ageing categories (1–30 days, 31–60 days, 61–90 days, and 91+ days overdue). This progression highlights the importance of timely collections and continuous monitoring of customer payment behavior.

The total receivable balance remained relatively stable at approximately $46,338, indicating consistent sales activity and customer billing levels throughout the reporting periods.

Ageing Bucket Movement Analysis

May 31, 2026

Receivable Distribution:

• Current: $12,183.83

• 1–30 Days: $6,372.24

• 31–60 Days: $27,776.15

• 61–90 Days: $0.00

• 91+ Days: $0.00

Interpretation: Most customer balances were concentrated within the 31–60-day category, indicating moderate collection delays but limited long-term overdue exposure at this stage.

Observation:

No balances exceeded 90 days
Receivables still largely collectible
Moderate collection pressure beginning to emerge

June 30, 2026

Receivable Distribution:

• Current: $6.76

• 1–30 Days: $12,183.83

• 31–60 Days: $6,372.24

• 61–90 Days: $27,776.15

• 91+ Days: $0.00

Interpretation: Customer balances continued ageing forward into older categories, particularly the 61–90-day bracket, indicating that several invoices remained unpaid for an extended period.

Observation:

Reduction in current receivables
Increase in overdue balances
Collection cycle slowing down

July 31, 2026

Receivable Distribution:

• Current: $0.00

• 1–30 Days: $6.76

• 31–60 Days: $12,183.83

• 61–90 Days: $6,372.24

• 91+ Days: $27,776.15

Interpretation: A significant portion of receivables progressed into the 91+ days overdue category, indicating elevated collection risk and potential exposure to delayed or doubtful payments.

Observation:

High concentration of aged receivables
Increased collection risk exposure
Potential pressure on operational cash flow

Collection Efficiency Analysis

Total Accounts Receivable:

Approximately $46,338.98

KPI Interpretation: The company maintains a moderate receivable balance relative to operational activity; however, the ageing trend indicates weakening collection efficiency over time.

Credit Risk Analysis

91+ Days Overdue Balance:

Approximately $27,776.15 by July 2026

KPI Interpretation: Over 50% of receivables had aged beyond 90 days by July, significantly increasing the risk of delayed collections or potential bad debts.

Strategic Observation: Long-outstanding balances may negatively impact liquidity and require follow-up actions such as collection reminders, payment arrangements, or allowance assessments.

Customer Concentration Analysis

Several customers represent significant portions of outstanding balances, including:

• Christiane Spenard

• Dr. Jennifer Moore

• Dr. Lindalin Martinez

• Dr. Michael Brown

Strategic Observation: High customer concentration within receivables increases dependency risk and emphasizes the need for active customer account management.

Working Capital Impact

Insight: As receivables age into older buckets, cash remains tied up in unpaid invoices rather than being available for operational use.

Operational Effect:

• Reduced liquidity flexibility

• Increased cash collection pressure

• Greater reliance on available bank balances or financing

Operational Observations

Positive Indicators:

Consistent sales and invoicing activity
Structured receivable monitoring process
Proper ageing categorization within QuickBooks Online
Visibility into overdue customer balances

Areas Requiring Attention:

Slow collection turnover
High 91+ overdue balances
Potential bad debt exposure
Increased working capital pressure
Customer concentration risk

Accounting & Reporting Strength Demonstrated

This report demonstrates:

• Accounts receivable monitoring

• Customer ageing analysis

• Credit control procedures

• Working capital awareness

• Cash flow risk assessment

• Financial reporting interpretation

• Collection performance analysis

Financial Insight:  The Accounts Receivable Ageing Summary Report reflects a business with active customer billing and revenue generation, but also highlights the importance of effective collection management. The progression of receivables into older ageing categories demonstrates increasing collection risk and emphasizes the need for proactive credit control procedures to maintain healthy cash flow and operational liquidity.

Accounts Payable (A/P) Ageing Summary Report — Financial Interpretation & KPI Analysis

Report Overview

Company: JiduffKelv Pharmaceutical Ltd
Report Type: Accounts Payable (A/P) Ageing Summary Report
Periods Reviewed:

• April 30, 2026

• June 30, 2026

• July 31, 2026

Accounting Method: Accrual Basis

Executive Financial Interpretation:  The Accounts Payable (A/P) Ageing Summary Report reflects the company’s outstanding supplier obligations categorized according to the length of time vendor invoices have remained unpaid. The report demonstrates how the business manages supplier balances, monitors payment obligations, and tracks short-term liabilities across multiple reporting periods.

The ageing movement across the reviewed periods shows how unpaid vendor balances gradually transitioned from current liabilities into older ageing categories such as 1–30 days, 31–60 days, 61–90 days, and 91 days and over. This progression provides insight into supplier payment patterns, working capital management, and short-term liquidity pressure.

The increasing concentration of balances within older ageing buckets by July 2026 indicates that a growing portion of supplier obligations remained unpaid for extended periods, emphasizing the importance of effective cash flow planning and vendor payment management.

Accounts Payable Ageing Analysis

April 30, 2026

Total Accounts Payable:

Approximately $9,982.10

Ageing Distribution:

• Current: $5,740.46

• 1–30 Days: $4,241.63

• 31–60 Days: $0.00

• 61–90 Days: $0.00

• 91+ Days: $0.00

Interpretation: Most supplier balances remained within current and short-term payment periods, indicating relatively healthy vendor payment management during the early reporting phase.

Operational Observation:

Low overdue exposure
Strong short-term supplier management
Controlled payable ageing structure

June 30, 2026

Total Accounts Payable: Approximately $28,665.60

Ageing Distribution:

• Current: $0.00

• 1–30 Days: $15,000.00

• 31–60 Days: $8,337.46

• 61–90 Days: $5,328.13

• 91+ Days: $0.00

Interpretation: Supplier obligations increased significantly during the period, with balances spreading into older ageing categories, suggesting rising operational purchases and slower payment turnover.

Operational Observation:

Increase in short-term payable obligations
Growth in supplier financing dependency
Emerging working capital pressure

July 31, 2026

Total Accounts Payable: Approximately $28,665.60

Ageing Distribution:

• Current: $0.00

• 1–30 Days: $0.00

• 31–60 Days: $15,000.00

• 61–90 Days: $8,337.46

• 91+ Days: $5,328.13

Interpretation: By July 2026, a significant portion of vendor balances had progressed into overdue categories exceeding 60 and 90 days, indicating increased payment delays and potential pressure on supplier relationships.

Operational Observation:

High overdue supplier balances
Increased short-term liquidity pressure
Potential vendor credit risk exposure
Need for stronger payable scheduling and cash planning

Working Capital & Liquidity Analysis

Supplier Financing Impact

Insight: The increase in aged payables suggests the company may be relying more heavily on supplier credit to support operational activities and inventory acquisition.

KPI Interpretation: While supplier credit can improve short-term cash preservation, excessive ageing may negatively impact vendor trust, purchasing flexibility, and future credit terms.

Cash Flow Implications

Accounts Payable Growth: Accounts payable increased from approximately $9,982 to $28,666 over the reporting periods.

Strategic Observation: Rising payables may temporarily improve cash retention, but prolonged unpaid balances can create operational and supplier relationship risks if not managed properly.

Vendor Concentration Analysis

Several suppliers represent significant payable balances, including:

• DigitalTech Systems Ltd

• Teva Pharmaceuticals Ltd

• Medline Industries

• Kimberly-Clark Professional

Strategic Observation: High supplier concentration increases operational dependency on key vendors and emphasizes the importance of maintaining healthy supplier payment relationships.

Payable Ageing Risk Analysis

91+ Days Overdue:

Approximately $5,328.13 by July 2026

KPI Interpretation: Vendor balances exceeding 90 days may indicate delayed payment cycles and increase the risk of supplier restrictions, penalties, or tightened credit terms.

Operational Concern: Long-outstanding supplier balances should be actively monitored and prioritized within cash flow management processes.

Operational Observations

Positive Indicators:

Proper payable ageing categorization
Structured supplier liability tracking
Active operational purchasing activity
Vendor balance monitoring within QuickBooks Online

Areas Requiring Monitoring:

Increasing overdue supplier balances
Liquidity pressure from payable accumulation
Vendor payment scheduling
Dependence on supplier credit financing
Potential strain on supplier relationships

Accounting & Reporting Strength Demonstrated

This report demonstrates:

• Accounts payable management

• Supplier ageing analysis

• Working capital monitoring

• Vendor liability tracking

• Liquidity and cash flow awareness

• Credit management analysis

• Financial reporting interpretation

• Short-term obligation monitoring

Financial Insight: The Accounts Payable Ageing Summary Report reflects an operationally active business utilizing supplier credit to support purchasing and inventory activities. While this approach supports short-term liquidity management, the progression of balances into older ageing categories highlights the need for stronger payable scheduling, proactive cash flow planning, and effective vendor relationship management to maintain long-term operational stability and supplier confidence.